CERVOMED INC (CRVO)
(Delayed Data from NSDQ)
$2.26 USD
+0.01 (0.44%)
Updated Jan 31, 2025 04:00 PM ET
After-Market: $2.26 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.26 USD
+0.01 (0.44%)
Updated Jan 31, 2025 04:00 PM ET
After-Market: $2.26 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum C VGM
Zacks News
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of 13.64% and 39.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 47.76% and 20.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CERVOMED INC (CRVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.